REPL — Replimune Group, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1737953 ·
Last close
$11.42
Market Cap
$942.98M
52W High
$12.20
52W Low
$1.50
ADV30
6,667,297
Next earnings
2026-06-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -71,527,000 | -70,930,000 | 333,590,000 | 122,951,000 | 123,051,000 |
| Sep 2025 | 0 | — | -83,914,000 | -83,100,000 | 389,450,000 | 102,298,000 | 126,114,000 |
| Jun 2025 | 0 | — | -90,002,000 | -86,693,000 | 469,507,000 | 97,373,000 | 132,792,000 |
| Mar 2025 | 0 | — | -78,777,000 | -74,130,000 | 551,328,000 | 111,119,000 | 135,485,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-277,914,000
Investing CF
$216,637,000
Financing CF
$10,485,000
CapEx
$-5,352,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.41
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,189,302,000
Inventory
—
Receivables
$2,955,000
ST Investments
$146,186,000
EBIT TTM
$-307,304,000
Pretax Income TTM
$-315,271,000
Interest Exp TTM
$7,967,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 0 | -259,854,000 | -247,297,000 | 551,328,000 | 135,485,000 | — | -192,250,000 |
| Mar 2024 | 0 | -232,853,000 | -215,794,000 | 487,722,000 | 113,214,000 | — | -185,467,000 |
| Mar 2023 | 0 | -174,166,000 | -174,284,000 | 646,591,000 | 91,299,000 | — | -128,050,000 |
| Mar 2022 | 0 | -115,144,000 | -118,036,000 | 461,192,000 | 49,963,000 | — | -82,180,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-172,891,000
OpCashFlow TTM
$0
Assets (Latest)
$551,328,000
Forward EPS
$-2.06
Max Pain — expiry 2026-06-26
max pain strike: $10.00 · spot: $11.35 · call oi: 3,639 · put oi: 5,971Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DBVT | DBV Technologies S.A. | $953.50M | $16.11 | — |
| SANA | Sana Biotechnology, Inc. | $932.28M | $3.35 | — |
| ODTX | Odyssey Therapeutics, Inc. | $890.98M | $18.55 | — |
| SLDB | Solid Biosciences Inc. | $865.37M | $8.79 | — |
| CGEM | Cullinan Therapeutics, Inc. | $1.09B | $17.75 | — |
News headlines (Yahoo Finance, 1h cache)
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
2026-06-17 20:15 · Yahoo
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
2026-06-01 17:01 · Yahoo
Why Is REPL Stock Gaining In Pre-Market Today?
2026-06-01 10:56 · Yahoo
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
2026-05-31 12:00 · Yahoo
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
2026-05-30 12:00 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-05-29 19:36 · Yahoo
REPL Stock Shot Up 80% Today – What’s The Deal With FDA?
2026-05-29 14:04 · Yahoo
Market Chatter: Replimune Plans to Resubmit Melanoma Therapy Application for FDA Approval
2026-05-29 12:21 · Yahoo
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
2026-05-29 12:00 · Yahoo
12 Health Care Stocks Moving In Wednesday's Intraday Session
2026-05-13 17:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.